Deanol in the management of involuntary movement disorders: A review

Daniel Casey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.

Original languageEnglish (US)
Pages (from-to)7-15
Number of pages9
JournalDisease of the Nervous System
Volume38
Issue number12 II
StatePublished - 1977
Externally publishedYes

Fingerprint

Deanol
Dyskinesias
Movement Disorders
Huntington Disease
Levodopa
Athetosis
Blepharospasm
Tourette Syndrome
Aptitude
Dystonia
Acetylcholine
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Deanol in the management of involuntary movement disorders : A review. / Casey, Daniel.

In: Disease of the Nervous System, Vol. 38, No. 12 II, 1977, p. 7-15.

Research output: Contribution to journalArticle

@article{85b52d2f968447c98258db8d79409958,
title = "Deanol in the management of involuntary movement disorders: A review",
abstract = "Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25{\%}-50{\%} of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.",
author = "Daniel Casey",
year = "1977",
language = "English (US)",
volume = "38",
pages = "7--15",
journal = "Disease of the Nervous System",
number = "12 II",

}

TY - JOUR

T1 - Deanol in the management of involuntary movement disorders

T2 - A review

AU - Casey, Daniel

PY - 1977

Y1 - 1977

N2 - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.

AB - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.

UR - http://www.scopus.com/inward/record.url?scp=0017762669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017762669&partnerID=8YFLogxK

M3 - Article

C2 - 145359

AN - SCOPUS:0017762669

VL - 38

SP - 7

EP - 15

JO - Disease of the Nervous System

JF - Disease of the Nervous System

IS - 12 II

ER -